Clinical trials
Terminated Amyotrophic Lateral Sclerosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 5 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 70 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Drexel University College of Medicine | 5 |
| University of Michigan | 4 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| Newron Sweden AB | 3 |
| Alector Inc. | 2 |
| Biogen | 2 |
| Columbia University | 2 |
| Cytokinetics | 2 |
| Flex Pharma, Inc. | 2 |
| Johns Hopkins University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amyotrophic Lateral Sclerosis | 70 |
| Motor Neuron Disease | 12 |
| Neurodegenerative Diseases | 7 |
| Movement Disorders | 5 |
| Frontotemporal Dementia | 3 |
| Neuromuscular Diseases | 3 |
| Muscular Dystrophy, Duchenne | 2 |
| Deglutition Disorders | 1 |
| Dysphonia | 1 |
| Dyspnea | 1 |
Trials
Showing 76 to 70 of 70. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.